Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Medical - Devices
P/S (TTM)
0.5
Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.
www.nevro.comNo one on the platform currently holds NVRO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 1,209,409 | $7.1M |
No one on the platform has traded NVRO yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $424M | +4.1% | $-2.09 | $-2.63–$-1.55 | — | 5 |
| 2027 | $446M | +5.3% | $-1.93 | $-2.24–$-1.45 | — | 3 |
| 2028 | $479M | +7.2% | $-1.57 | $-1.66–$-1.53 | — | 1 |
| 2029 | $503M | +5.2% | $-1.26 | $-1.33–$-1.23 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-06 | $-0.91 | $-0.70 | +23.1% |
| 2024-11-11 | $-0.82 | $-0.51 | +37.8% |
| 2024-08-06 | $-0.63 | $-0.43 | +31.7% |
| 2024-05-07 | $-1.02 | $-0.70 | +31.4% |
| 2024-02-21 | $-0.50 | $-0.25 | +50.0% |
| 2023-11-01 | $-0.77 | $-0.65 | +15.6% |
| 2023-08-01 | $-0.68 | $-0.69 | -1.5% |
| 2023-04-26 | $-1.06 |
| $-0.98 |
| +7.5% |
| $258M |
| — |
| LSBLakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $26M | — |
| SISIShineco, Inc. | $0.00 | +0.00% | $63 | — |
Source: Financial Modeling Prep · peers by sector/industry
$MLSS all about the contacts. the best in biz is based on contacts $NVRO is where new BoD was from
View on StockTwits ↗$MLSS someone took size .8950-.91 we MUST be close $NVRO executives ?
View on StockTwits ↗$MLSS Table Is Set: Everyone needs to eat. In fact, everyone loves to eat a great big home cooked meal, but not everyone loves to do what it takes to deliver that arduous task. That brings us to what potentially could be one of the most savoring investments in the micro cap space that just might be all set up for making that brokerage account adequately full when it’s all said and done. The investment is Milestone Scientific (MLSS .90) a medical device company that specializes in a device that delivers a one of a kind, AI pressurized syringe for the epidural market today, but the platform could bolster many new applications in the not too distant future. The reality is the company has done a lot of the heavy lifting to get themselves to invite as many new shareholders to the table that we believe is set to eat. Shanth Thiyagalingam Brought into MLSS 3 weeks ago COULD be the Chef needed to find all the ingredients $NVRO $ABT
View on StockTwits ↗$MLSS someone collecting blocks of stock CANNOT BE LONG!!!!! $NVRO
View on StockTwits ↗$MLSS This is NOT 1.00 stock much longer. I noticed new BoD was at $NVRO 3-50 then 130 cmon 5.00
View on StockTwits ↗$NVRO With groundbreaking tech, strong IP, & rising international demand, Nevro might be undervalued even with the Globus Medical's acquisition. https://biotechhealthx.com/biotech-news/nevro-nvro-could-surge-beyond-its-buyout-offer-in-2025/
View on StockTwits ↗$NVRO Digging Nevro's AI-powered pain management tech. HFX AdaptivAI looks promising. Might initiate a small position to play the chronic pain innovation angle. Watching closely for clinical expansion potential. noteworthy article: https://beyondspx.com/article/nevro-corp-nvro-delivering-innovative-solutions-for-chronic-pain-management
View on StockTwits ↗$NVRO reported -1.41 EPS and 105.55 revenue for Q4. http://www.estimize.com/intro/nvro?chart=historical&metric_name=eps&utm_content=NVRO&ut
View on StockTwits ↗$NVRO reports after the close, Estimize Consensus +0.06 EPS and +1.79M Revs compared to WS http://www.estimize.com/nvro/fq4-2024?utm_conten
View on StockTwits ↗$NVRO Nevro upgraded to Hold from Underperform at Jefferies Jefferies upgraded Nevro to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its shares for $5.85 per share.
View on StockTwits ↗I found you an Overbought RSI (Relative Strength Index) on the daily chart of Nevro Corp. Is that bullish or bearish? $NVRO #Nevro #RsiOverbought #NYSE
View on StockTwits ↗$NVRO https://stocks.apple.com/A1x9npE6ySxONebBwJHq_7Q Sad ending. $250M valuation is embarrassing.
View on StockTwits ↗$NVRO Stryker announced it is selling off its spinal implant business. They would have been the most logical of the big strategic companies that have a spinal business to acquire NVRO. Makes you wonder if the stim market is stagnating or going backwards.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.